SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015528
Filing Date
2021-11-10
Accepted
2021-11-10 16:41:06
Documents
60
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sgtx-20210930x10q.htm   iXBRL 10-Q 1837794
2 EX-10.1 sgtx-20210930xex10d1.htm EX-10.1 26186
3 EX-31.1 sgtx-20210930xex31d1.htm EX-31.1 36214
4 EX-32.1 sgtx-20210930xex32d1.htm EX-32.1 10210
  Complete submission text file 0001558370-21-015528.txt   5862377

Data Files

Seq Description Document Type Size
5 EX-101.SCH sgtx-20210930.xsd EX-101.SCH 37625
6 EX-101.CAL sgtx-20210930_cal.xml EX-101.CAL 44933
7 EX-101.DEF sgtx-20210930_def.xml EX-101.DEF 129672
8 EX-101.LAB sgtx-20210930_lab.xml EX-101.LAB 381185
9 EX-101.PRE sgtx-20210930_pre.xml EX-101.PRE 271911
10 EXTRACTED XBRL INSTANCE DOCUMENT sgtx-20210930x10q_htm.xml XML 794569
Mailing Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142
Business Address 100 BINNEY STREET STE 600 CAMBRIDGE MA 02142 617-336-7540
Sigilon Therapeutics, Inc. (Filer) CIK: 0001821323 (see all company filings)

IRS No.: 474005543 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39746 | Film No.: 211397370
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences